Protein Flexibility and Dissociation Pathway Differentiation Can Explain Onset of Resistance Mutations in Kinases

Overview

Journal Angew Chem Int Ed Engl

Specialty Chemistry

Date 2022 Apr 29

PMID 35486370

Authors

Mrinal Shekhar

Zachary Smith

Markus A Seeliger

Pratyush Tiwary

Affiliations

Soon will be listed here.

Abstract

Understanding how mutations render a drug ineffective is a problem of immense relevance. Often the mechanism through which mutations cause drug resistance can be explained purely through thermodynamics. However, the more perplexing situation is when two proteins have the same drug binding affinities but different residence times. In this work, we demonstrate how all-atom molecular dynamics simulations using recent developments grounded in statistical mechanics can provide a detailed mechanistic rationale for such variances. We discover dissociation mechanisms for the anti-cancer drug Imatinib (Gleevec) against wild-type and the N368S mutant of Abl kinase. We show how this point mutation triggers far-reaching changes in the protein's flexibility and leads to a different, much faster, drug dissociation pathway. We believe that this work marks an efficient and scalable approach to obtain mechanistic insight into resistance mutations in biomolecular receptors that are hard to explain using a structural perspective.

Citing Articles

Pathway Specific Unbinding Free Energy Profiles of Ritonavir Dissociation from HIV-1 Protease.

Vig E, Sun J, Chang C Biochemistry. 2025; 64(4):940-952.

PMID: 39924810 PMC: 11844232. DOI: 10.1021/acs.biochem.4c00560.

Machine learning-augmented molecular dynamics simulations (MD) reveal insights into the disconnect between affinity and activation of ZTP riboswitch ligands.

Fullenkamp C, Mehdi S, Jones C, Tenney L, Pichling P, Prestwood P bioRxiv. 2024; .

PMID: 39314358 PMC: 11419147. DOI: 10.1101/2024.09.13.612887.

Calculating Protein-Ligand Residence Times Through State Predictive Information Bottleneck based Enhanced Sampling.

Lee S, Wang D, Seeliger M, Tiwary P bioRxiv. 2024; .

PMID: 38659748 PMC: 11042289. DOI: 10.1101/2024.04.16.589710.

Data-driven classification of ligand unbinding pathways.

Ray D, Parrinello M Proc Natl Acad Sci U S A. 2024; 121(10):e2313542121.

PMID: 38412121 PMC: 10927508. DOI: 10.1073/pnas.2313542121.

Enhanced Sampling with Machine Learning.

Mehdi S, Smith Z, Herron L, Zou Z, Tiwary P Annu Rev Phys Chem. 2024; 75(1):347-370.

PMID: 38382572 PMC: 11213683. DOI: 10.1146/annurev-physchem-083122-125941.

References

Cowan-Jacob S, Fendrich G, Floersheimer A, Furet P, Liebetanz J, Rummel G . Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Acta Crystallogr D Biol Crystallogr. 2006; 63(Pt 1):80-93. PMC: 2483489. DOI: 10.1107/S0907444906047287. View

Wood E, Truesdale A, McDonald O, Yuan D, Hassell A, Dickerson S . A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004; 64(18):6652-9. DOI: 10.1158/0008-5472.CAN-04-1168. View

Hamelberg D, Mongan J, McCammon J . Accelerated molecular dynamics: a promising and efficient simulation method for biomolecules. J Chem Phys. 2004; 120(24):11919-29. DOI: 10.1063/1.1755656. View

De Bondt H, Rosenblatt J, Jancarik J, Jones H, MORGAN D, Kim S . Crystal structure of cyclin-dependent kinase 2. Nature. 1993; 363(6430):595-602. DOI: 10.1038/363595a0. View

Nielsen G, Jonker H, Vajpai N, Grzesiek S, Schwalbe H . Kinase in motion: insights into the dynamic nature of p38α by high-pressure NMR spectroscopic studies. Chembiochem. 2013; 14(14):1799-806. DOI: 10.1002/cbic.201300170. View

Pitsawong W, Buosi V, Otten R, Agafonov R, Zorba A, Kern N . Dynamics of human protein kinase Aurora A linked to drug selectivity. Elife. 2018; 7. PMC: 6054532. DOI: 10.7554/eLife.36656. View

Mondal J, Tiwary P, Berne B . How a Kinase Inhibitor Withstands Gatekeeper Residue Mutations. J Am Chem Soc. 2016; 138(13):4608-15. DOI: 10.1021/jacs.6b01232. View

Meng Y, Gao C, Clawson D, Atwell S, Russell M, Vieth M . Predicting the Conformational Variability of Abl Tyrosine Kinase using Molecular Dynamics Simulations and Markov State Models. J Chem Theory Comput. 2018; 14(5):2721-2732. PMC: 6317529. DOI: 10.1021/acs.jctc.7b01170. View

Schindler T, Bornmann W, Pellicena P, Miller W, Clarkson B, Kuriyan J . Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 2000; 289(5486):1938-42. DOI: 10.1126/science.289.5486.1938. View

10.

Meng Y, Shukla D, Pande V, Roux B . Transition path theory analysis of c-Src kinase activation. Proc Natl Acad Sci U S A. 2016; 113(33):9193-8. PMC: 4995974. DOI: 10.1073/pnas.1602790113. View

11.

Copeland R, Pompliano D, Meek T . Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov. 2006; 5(9):730-9. DOI: 10.1038/nrd2082. View

12.

Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S . The protein kinase complement of the human genome. Science. 2002; 298(5600):1912-34. DOI: 10.1126/science.1075762. View

13.

Jabbour E, Cortes J, Kantarjian H . Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin Lymphoma Myeloma Leuk. 2013; 13(5):515-29. PMC: 4160831. DOI: 10.1016/j.clml.2013.03.018. View

14.

Narayan B, Buchete N, Elber R . Computer Simulations of the Dissociation Mechanism of Gleevec from Abl Kinase with Milestoning. J Phys Chem B. 2021; 125(22):5706-5715. PMC: 8192492. DOI: 10.1021/acs.jpcb.1c00264. View

15.

Shan Y, Kim E, Eastwood M, Dror R, Seeliger M, Shaw D . How does a drug molecule find its target binding site?. J Am Chem Soc. 2011; 133(24):9181-3. PMC: 3221467. DOI: 10.1021/ja202726y. View

16.

Druker B, Guilhot F, OBrien S, Gathmann I, Kantarjian H, Gattermann N . Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355(23):2408-17. DOI: 10.1056/NEJMoa062867. View

17.

Casasnovas R, Limongelli V, Tiwary P, Carloni P, Parrinello M . Unbinding Kinetics of a p38 MAP Kinase Type II Inhibitor from Metadynamics Simulations. J Am Chem Soc. 2017; 139(13):4780-4788. DOI: 10.1021/jacs.6b12950. View

18.

Dhar A, Samiotakis A, Ebbinghaus S, Nienhaus L, Homouz D, Gruebele M . Structure, function, and folding of phosphoglycerate kinase are strongly perturbed by macromolecular crowding. Proc Natl Acad Sci U S A. 2010; 107(41):17586-91. PMC: 2955104. DOI: 10.1073/pnas.1006760107. View

19.

Narayan B, Fathizadeh A, Templeton C, He P, Arasteh S, Elber R . The transition between active and inactive conformations of Abl kinase studied by rock climbing and Milestoning. Biochim Biophys Acta Gen Subj. 2019; 1864(4):129508. PMC: 7012767. DOI: 10.1016/j.bbagen.2019.129508. View

20.

Jagger B, Lee C, Amaro R . Quantitative Ranking of Ligand Binding Kinetics with a Multiscale Milestoning Simulation Approach. J Phys Chem Lett. 2018; 9(17):4941-4948. PMC: 6443090. DOI: 10.1021/acs.jpclett.8b02047. View